AnaptysBio (NASDAQ:ANAB) Shares Down 5.4% – Should You Sell?

AnaptysBio, Inc. (NASDAQ:ANAB)’s stock price fell 5.4% during trading on Monday . The stock traded as low as $20.51 and last traded at $20.51. 10,002 shares traded hands during trading, a decline of 97% from the average session volume of 342,041 shares. The stock had previously closed at $21.68.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ANAB. Truist Financial boosted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of AnaptysBio in a report on Thursday, October 31st. JPMorgan Chase & Co. lifted their target price on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Wedbush reiterated an “outperform” rating and issued a $42.00 price target on shares of AnaptysBio in a report on Thursday, September 26th. Finally, UBS Group raised their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $55.73.

AnaptysBio Stock Down 0.3 %

The business has a 50-day simple moving average of $33.59 and a 200-day simple moving average of $29.94. The company has a market cap of $545.39 million, a PE ratio of -3.13 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. On average, research analysts forecast that AnaptysBio, Inc. will post -6.84 EPS for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In related news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the business’s stock in a transaction dated Wednesday, August 14th. The stock was acquired at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the purchase, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now owns 4,744 shares in the company, valued at approximately $189,333.04. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the stock in a transaction on Wednesday, August 14th. The shares were acquired at an average cost of $36.50 per share, for a total transaction of $9,999,978.00. Following the purchase, the insider now owns 7,794,996 shares in the company, valued at $284,517,354. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 22,440 shares of company stock valued at $892,936 over the last ninety days. Corporate insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently modified their holdings of ANAB. Frazier Life Sciences Management L.P. raised its holdings in AnaptysBio by 140.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after acquiring an additional 1,265,891 shares during the last quarter. StemPoint Capital LP increased its holdings in shares of AnaptysBio by 499.0% in the first quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock valued at $6,070,000 after purchasing an additional 224,548 shares during the last quarter. Victory Capital Management Inc. lifted its position in AnaptysBio by 677.9% during the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after buying an additional 206,750 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after buying an additional 168,813 shares during the last quarter. Finally, Platinum Investment Management Ltd. acquired a new position in AnaptysBio during the first quarter worth $1,490,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.